✕
Login
Register
EN
Translate page
EN
English
ES
Español
FR
Français
DE
Deutsch
ZH
中文
AR
العربية
PT
Português
RU
Русский
JA
日本語
KO
한국어
HI
हिन्दी
IT
Italiano
Back to News
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC
Benzinga Newsdesk
www.benzinga.com
Neutral 88.7%
Neg 0%
Neu 88.7%
Pos 0%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment